Page last updated: 2024-08-25

bexarotene and Necrosis

bexarotene has been researched along with Necrosis in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S	1
Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W	1

Trials

1 trial(s) available for bexarotene and Necrosis

Article	Year
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:6 Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured	2011

Article

Year

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:6

Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured

2011

Other Studies

1 other study(ies) available for bexarotene and Necrosis

Article	Year
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:5 Suppl 1 Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fever; Granuloma; Humans; Hydroxamic Acids; Hypolipidemic Agents; Middle Aged; Mycosis Fungoides; Necrosis; Remission Induction; Skin; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat	2008

Article

Year

Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.

Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:5 Suppl 1

Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fever; Granuloma; Humans; Hydroxamic Acids; Hypolipidemic Agents; Middle Aged; Mycosis Fungoides; Necrosis; Remission Induction; Skin; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat

2008